We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

A Study of the Use of Chartis System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: April 12, 2010
Last Update Posted: May 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Pulmonx, Inc.
Use of the Chartis® Assessment System prior to EBV Treatment

Condition Intervention
Emphysema Device: Chartis System Device: Endobronchial Valve (EBV) Treatment

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study of the Use of Chartis System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR) in Subjects With Heterogeneous Emphysema

Resource links provided by NLM:

Further study details as provided by Pulmonx, Inc.:

Primary Outcome Measures:
  • Lung Volume Change [ Time Frame: 30 Days ]

Enrollment: 96
Study Start Date: January 2012
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Chartis System-EBV Treatment
Subjects with heterogeneous emphysema, had their collateral ventilation status in the target treatment lobe assessed using the Chartis System (CV- or CV+) and underwent endobronchial lung volume reduction (ELVR) with endobronchial valves (EBV).
Device: Chartis System
The Chartis System provides a value that represents the quantification of the average resistance to airflow through collateral airways.
Device: Endobronchial Valve (EBV) Treatment
The endobronchial valve is designed to induce target lobe volume reduction.

Detailed Description:
This is a multi-center study which will enroll up to 120 patients. Subjects will undergo a Chartis Assessment prior to EBV treatment. The Chartis assessment will determine the presence or absence of collateral ventilation, a potential determining factor in the success of EBV therapy. This study is not randomized; all subjects are eligible to receive EBV Treatment, regardless of Chartis Assessment outcome. Follow-up data will only be collected on those patients that meet the Chartis inclusion criteria.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Heterogeneous emphysema
  • Able to obtain a Chartis value during Assessment

Exclusion Criteria:

  • Any co-existing major medical problems that would not make it possible for the subject to tolerate a bronchoscopic procedure.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01101958

University of Heidelberg
Heidelberg, Germany, 69126
UMC Groningen
Groningen, Netherlands
Sponsors and Collaborators
Pulmonx, Inc.
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pulmonx, Inc.
ClinicalTrials.gov Identifier: NCT01101958     History of Changes
Other Study ID Numbers: 630-0011
First Submitted: April 8, 2010
First Posted: April 12, 2010
Results First Submitted: December 4, 2013
Results First Posted: January 23, 2014
Last Update Posted: May 12, 2017
Last Verified: April 2017

Additional relevant MeSH terms:
Pulmonary Emphysema
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases